Profile data is unavailable for this security.
About the company
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company's development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.
- Revenue in USD (TTM)0.00
- Net income in USD30.31m
- Incorporated2015
- Employees13.00
- LocationTectonic Therapeutic Inc490 Arsenal Way, Suite 210WATERTOWN 02472United StatesUSA
- Phone+1 (339) 666-3320
- Fax+1 (302) 655-5049
- Websitehttps://tectonictx.com/
More ▼
Mergers & acquisitions
| Acquired company | TECX:NMQ since announced | Transaction value |
|---|---|---|
| Tectonic Therapeutic Inc | 1,152.55% | -- |
Data delayed at least 15 minutes, as of Jul 24 2024 17:42 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Design Therapeutics Inc | 0.00 | -58.67m | 228.80m | 57.00 | -- | 0.8488 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Chromadex Corp | 83.17m | -3.53m | 231.90m | 106.00 | -- | 7.97 | -- | 2.79 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 232.02m | 51.00 | -- | 1.26 | -- | 14.37 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 233.35m | 50.00 | -- | 1.75 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 234.36m | 58.00 | -- | 1.59 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 235.18m | 274.00 | -- | 1.13 | -- | 3.30 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| bluebird bio Inc | 21.73m | -91.17m | 236.04m | 323.00 | -- | 0.5963 | -- | 10.86 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 238.25m | 10.00 | -- | 2.10 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 238.27m | 49.00 | -- | 5.36 | -- | 2,941.58 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Rezolute Inc | 0.00 | -58.21m | 239.96m | 51.00 | -- | 2.64 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Gossamer Bio Inc | 0.00 | -172.58m | 242.05m | 135.00 | -- | 9.06 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
| Tectonic Therapeutic Inc | 0.00 | 30.31m | 242.23m | 13.00 | 1.98 | 0.6921 | 7.92 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 244.79m | 14.00 | -- | 2.74 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Codexis Inc | 74.23m | -65.13m | 260.36m | 174.00 | -- | 3.28 | -- | 3.51 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Data as of Jul 24 2024. Currency figures normalised to Tectonic Therapeutic Inc's reporting currency: US Dollar USD
28.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 28 Jun 2024 | 2.02m | 13.68% |
| EcoR1 Capital, LLCas of 20 Jun 2024 | 849.14k | 5.76% |
| BML Capital Management LLCas of 20 Jun 2024 | 400.36k | 2.72% |
| Adar1 Capital Management LLCas of 31 Mar 2024 | 328.25k | 2.23% |
| Verition Fund Management LLCas of 31 Mar 2024 | 160.01k | 1.09% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 155.06k | 1.05% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 102.65k | 0.70% |
| Newtyn Management LLCas of 31 Mar 2024 | 92.87k | 0.63% |
| Aisling Capital Management LPas of 31 Mar 2024 | 83.81k | 0.57% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 73.72k | 0.50% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
